StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Sangamo Therapeutics's total assets was $59.97M at Mar 31, 2026. For fiscal 2025 it was $59.75M, down 41.2% from the year before. Over ten years it grew -12.1% a year on average. The highest annual figure on record is $938.55M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$59.75M-41.2%
FY2024Dec 31, 2024$101.64M-38.5%
FY2023Dec 31, 2023$165.32M-70.6%
FY2022Dec 31, 2022$562.51M-22.1%
FY2021Dec 31, 2021$721.92M-23.1%
FY2020Dec 31, 2020$938.55M+47.2%
FY2019Dec 31, 2019$637.52M+8.0%
FY2018Dec 31, 2018$590.40M+105.9%
FY2017Dec 31, 2017$286.74M+81.6%
FY2016Dec 31, 2016$157.89M-27.3%
FY2015Dec 31, 2015$217.24M-10.7%
FY2014Dec 31, 2014$243.21M+72.7%
FY2013Dec 31, 2013$140.84M+70.6%
FY2012Dec 31, 2012$82.53M-5.5%
FY2011Dec 31, 2011$87.34M+38.6%
FY2010Dec 31, 2010$63.00M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$59.97M-30.4%
Q4 FY2025Dec 31, 2025$59.75M-41.2%
Q3 FY2025Sep 30, 2025$88.64M-20.3%
Q2 FY2025Jun 30, 2025$97.56M+4.9%
Q1 FY2025Mar 31, 2025$86.17M-33.2%
Q4 FY2024Dec 31, 2024$101.64M-38.5%
Q3 FY2024Sep 30, 2024$111.26M-49.4%
Q2 FY2024Jun 30, 2024$93.01M-71.4%
Q1 FY2024Mar 31, 2024$128.96M-70.7%
Q4 FY2023Dec 31, 2023$165.32M-70.6%
Q3 FY2023Sep 30, 2023$219.70M-63.0%
Q2 FY2023Jun 30, 2023$325.07M-47.3%
Q1 FY2023Mar 31, 2023$440.57M-32.7%
Q4 FY2022Dec 31, 2022$562.51M-22.1%
Q3 FY2022Sep 30, 2022$593.91M-23.1%
Q2 FY2022Jun 30, 2022$617.13M-26.1%
Q1 FY2022Mar 31, 2022$654.31M-25.4%
Q4 FY2021Dec 31, 2021$721.92M-23.1%
Q3 FY2021Sep 30, 2021$772.40M-19.9%
Q2 FY2021Jun 30, 2021$835.36M-6.6%
Q1 FY2021Mar 31, 2021$877.10M+50.1%
Q4 FY2020Dec 31, 2020$938.55M+47.2%
Q3 FY2020Sep 30, 2020$963.71M+50.5%
Q2 FY2020Jun 30, 2020$894.66M+32.8%
Q1 FY2020Mar 31, 2020$584.28M+7.7%
Q4 FY2019Dec 31, 2019$637.52M+8.0%
Q3 FY2019Sep 30, 2019$640.22M+5.5%
Q2 FY2019Jun 30, 2019$673.48M+7.3%
Q1 FY2019Mar 31, 2019$542.73M+93.0%
Q4 FY2018Dec 31, 2018$590.40M+105.9%
Q3 FY2018Sep 30, 2018$606.60M+124.8%
Q2 FY2018Jun 30, 2018$627.73M+121.8%
Q1 FY2018Mar 31, 2018$281.17M+91.5%
Q4 FY2017Dec 31, 2017$286.74M+81.6%
Q3 FY2017Sep 30, 2017$269.79M+63.5%
Q2 FY2017Jun 30, 2017$282.99M+56.4%
Q1 FY2017Mar 31, 2017$146.81M–
Q4 FY2016Dec 31, 2016$157.89M–
Q3 FY2016Sep 30, 2016$164.98M–
Q2 FY2016Jun 30, 2016$180.91M–

More Sangamo Therapeutics figures

See a number that looks wrong?